Becton Dickinson and Co (NYSE:BDX) EVP James C. Lim sold 9,299 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $263.53, for a total value of $2,450,565.47. Following the completion of the sale, the executive vice president now directly owns 33,041 shares in the company, valued at approximately $8,707,294.73. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Becton Dickinson and stock opened at $261.00 on Thursday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.09 and a quick ratio of 0.67. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The business’s fifty day moving average price is $252.38 and its two-hundred day moving average price is $245.32. The company has a market capitalization of $69.76 billion, a P/E ratio of 23.71, a PEG ratio of 1.87 and a beta of 1.13.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.91 earnings per share. On average, research analysts expect that Becton Dickinson and Co will post 11.68 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.18%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is currently 27.97%.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Morgan Stanley raised its position in shares of Becton Dickinson and by 66.7% during the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after buying an additional 1,955,095 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Becton Dickinson and by 12,995.3% in the second quarter. Nuveen Asset Management LLC now owns 1,429,875 shares of the medical instruments supplier’s stock valued at $360,343,000 after acquiring an additional 1,418,956 shares in the last quarter. Thoroughbred Financial Services LLC boosted its holdings in shares of Becton Dickinson and by 25,302.2% in the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock valued at $99,094,000 after acquiring an additional 987,039 shares in the last quarter. FMR LLC increased its stake in shares of Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after acquiring an additional 842,590 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Becton Dickinson and by 2.3% during the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after acquiring an additional 520,350 shares during the period. Hedge funds and other institutional investors own 84.26% of the company’s stock.

A number of research analysts recently commented on the company. Piper Jaffray Companies lowered their price objective on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Co raised their target price on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Raymond James upped their price target on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research report on Friday, June 28th. Finally, ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $266.55.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: What is the yield curve?

Insider Buying and Selling by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.